Characteristics | Training series | Testing series | |
GSE30219 | GSE31210 | TCGA | |
Platform | HG-U133_Plus_2 | HG-U133_Plus_2 | IlluminaHiSeq |
Patients, n | 293 | 226 | 1014 |
>60 | 162 | 118 | 721 |
≤60 | 130 | 108 | 265 |
NA | 1 | 0 | 28 |
Gender | |||
Female | 43 | 121 | 406 |
Male | 250 | 105 | 608 |
Stage | |||
I | 152 | 168 | 518 |
II | 77 | 58 | 283 |
III | 56 | 0 | 168 |
IV | 7 | 0 | 33 |
NA | 1 | 0 | 12 |
Survival | |||
Dead | 200 | 35 | 284 |
Alive | 93 | 191 | 730 |
NA, not applicable; NSCLC, non-small cell lung cancer; TCGA, The Cancer Genome Atlas.